• Miscellaneous ocular agents

Cimerli Generic Name & Formulations

General Description

Ranibizumab-eqrn 6mg/mL (0.3mg), 10mg/mL (0.5mg); soln for oph intravitreal inj; preservative-free.

Pharmacological Class

Vascular endothelial growth factor (VEGF) inhibitor.

How Supplied

Single-dose vial (2mL)—1


Generic Availability


Cimerli Indications


Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).

Cimerli Dosage and Administration


Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.


Not established.

Cimerli Contraindications


Ocular or periocular infections.

Cimerli Boxed Warnings

Not Applicable

Cimerli Warnings/Precautions


Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy. Nursing mothers.

Cimerli Pharmacokinetics

See Literature

Cimerli Interactions

Cimerli Adverse Reactions

Adverse Reactions

Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events (with DME, DR); possible embryo-fetal toxicity.

Cimerli Clinical Trials

See Literature

Cimerli Note

Not Applicable

Cimerli Patient Counseling

See Literature